Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big (NYSE:LLY)

Summary by Seeking Alpha
Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I maintain a hold rating on LLY stock.

4 Articles

Seeking AlphaSeeking Alpha
Lean Right

With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big (NYSE:LLY)

Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I maintain a hold rating on LLY stock.

·United States
Read Full Article
bionity.combionity.com
Reposted by
analytica-world.comanalytica-world.com

An Eth Spin-Off Wants to Bring the Gene Scissors Into the Clinic

Using CRISPR/Cas technology, researchers can precisely edit the genome to treat hereditary diseases. However, this requires early detection of unwanted cuts in the genome. Pioneer Fellow Lilly van de Venn is developing such testing methods. She's rather introverted, says Lilly...

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Eli Lilly buys Adverum in eye disease gene therapy punt - Pharmaceutical Technology

Eli Lilly has agreed to acquire cash-strapped Adverum as it eyes the lucrative wet AMD market.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Monday, October 27, 2025.
Sources are mostly out of (0)

Similar News Topics

Eli Lilly icon

Eli Lilly

AMD icon

AMD

Switzerland icon

Switzerland

News
For You
SearchBlindspotLocal